Britain is reviewing the rules for integrating artificial intelligence into healthcare before expanding its adoption

Britain is reviewing the rules for integrating artificial intelligence into healthcare before expanding its adoption
Britain is moving to reconsider the rules of regulation Artificial intelligence in healthcare, after new recommendations called for developing a more flexible system that would allow accelerating the use of technologies within the National Health Service "National Health Service" (NHS), while maintaining patient safety and public confidence.
The recommendations came after a year-long investigation conducted by the Independent National Commission for the Regulation of Artificial Intelligence in Healthcare, which included more than… 12 A thousand people From patients, members of the public, clinicians, health sector leaders, technology developers and industry representatives.
The consultations showed that there is broad acceptance of the use of artificial intelligence in health services, but only on the condition that there are strong safety standards, clear human supervision, and transparency that allows the patient to know when these technologies are being used in their care.
Artificial intelligence enters the NHS
AI in healthcare is already being used within NHS services in a number of clinical and administrative tasks, including supporting early detection of strokes and skin cancer.
Some services also use voice tools powered by artificial intelligence to reduce administrative burdens, allowing doctors to devote more time to dealing directly with patients.
But the rapid expansion of these uses poses a new regulatory challenge, because AI-based tools differ from many traditional medical devices, whose properties remain relatively stable after approval.

Intelligent systems may change as software is updated, models are modified, or they are exposed to new data in actual usage environments, which makes monitoring them after adoption even more important.
Current rules are being challenged
The Committee believes that traditional accreditation systems may not be adequate to address Artificial intelligence in healthcare, because it depends largely on evaluating the product before it is released for use, while the performance of smart systems may change over time.
This is why she called for moving from the idea of one-time approval to a model based on continuous monitoring throughout the period of operation of the medical device.
These recommendations reflect what was demonstrated by the participation of more than 12,000 people in the study, as many expressed their willingness to benefit from artificial intelligence techniques, but in return they demanded actual human supervision and clear knowledge of how to use technology in their treatment.
Through these proposals, the committee is trying to achieve a balance between accelerating medical innovation and preventing insufficiently tested tools from reaching patients.
Gradual adoption before widespread use
One of the most prominent proposals is to create a system Interim approval For new technologies, they do not go directly from development to full clinical use.
The committee likened the idea to restrictions imposed on a learner driver, where promising systems begin to operate under more stringent controls, intensive monitoring, and specific protection measures.
During this phase, the system's performance and safety can be evaluated within real healthcare environments, before being allowed to gradually move into wider use.
This approach aims to reduce two opposing risks: delaying the arrival of innovations that may benefit patients, or rushing to use tools that have not received sufficient testing.
For a broader understanding of usage paths artificial intelligence In health care And its impact on diagnosis and medical services. Read also: Artificial intelligence in health care…pathways of transformation and innovation.
Oversight continues after approval
The committee proposes that AI-powered medical devices continue to be monitored even after they enter hospitals, rather than relying solely on data collected before they are approved.
This oversight allows regulators to monitor how the technology performs in reality, and monitor problems that may arise after updates or when used with different patient groups.
The committee also requested grants UK Medicines and Healthcare Products Regulatory Agency (MHRA). Stronger powers to intervene when tools do not meet required safety or performance standards.
This trend intersects with the third goal of the Sustainable Development Goals on good health and well-being, especially with linking medical innovation to patient safety and quality of health services.
The patient wants to know the role of artificial intelligence
Transparency is a key focus of the new recommendations, as the committee believes that patients should be able to easily access information regarding AI-powered medical devices.
This information includes each device's safety record and any reported incidents or adverse events, giving patients a clearer picture of the performance of the technology used in their care.
The consultations also showed that the public wants to know when Artificial intelligence in healthcare Part of the diagnosis or treatment process, with the doctor continuing to play a role in supervision and decision-making.
The development of these systems and their accompanying rules intersects with the ninth goal of the Sustainable Development Goals on industry, innovation and infrastructure, especially with the need to build a regulatory environment that allows medical innovation to expand in a safe and responsible manner.
The British government and the MHRA will consider the recommendations before issuing a formal response, meaning the proposals have not yet become binding rules.
In light of these developments, it is indicated The Earth Guards Foundation Until the expansion of artificial intelligence in health care, it requires a regulatory system that keeps pace with the speed of its development, so that it allows innovation and at the same time ensures clarity of responsibility, continued human supervision, and protection of patients during the stages of testing and use.




